PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31215459-1	2019	OBJECTIVE: A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models.	TAE226	111-117	insulin like growth factor 1 receptor	Homo sapiens	63-100	
31215459-1	2019	OBJECTIVE: A dual inhibitor of focal adhesion kinase (FAK) and insulin-like growth factor 1 receptor (IGF-1R), TAE226, was evaluated in a panel of cancer cell lines, MIA PaCa-2 human pancreatic tumor and 4T1 murine breast tumor models.	TAE226	111-117	insulin like growth factor 1 receptor	Homo sapiens	102-108	
18628478-9	2008	The activities of FAK, IGF-IR, and AKT were suppressed by TAE226 and subsequent dephosphorylation of BAD at Ser(136) occurred, resulting in caspase-mediated apoptosis.	TAE226	58-64	insulin like growth factor 1 receptor	Homo sapiens	23-29	
18628478-11	2008	CONCLUSIONS: These results suggest that TAE226, a dual tyrosine kinase inhibitor for FAK and IGF-IR, could become a new remedy for Barrett"s esophageal adenocarcinoma.	TAE226	40-46	insulin like growth factor 1 receptor	Homo sapiens	93-99	
21338601-0	2011	Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.	TAE226	44-50	insulin like growth factor 1 receptor	Homo sapiens	81-87	
19020730-0	2008	TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	37-43	
19020730-4	2008	TAE226, a novel small molecule compound, is a potent ATP competitive inhibitor of FAK and IGF-IR.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	90-96	
19020730-5	2008	TAE226 can block FAK and IGF-IR signaling pathways.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	25-31	
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	77-83	insulin like growth factor 1 receptor	Homo sapiens	63-69	
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	77-83	insulin like growth factor 1 receptor	Homo sapiens	161-167	
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	102-108	insulin like growth factor 1 receptor	Homo sapiens	63-69	
17431114-4	2007	We hypothesized that inhibiting the phosphorylation of FAK and IGF-IR by NVP-TAE226 (hereafter called TAE226), a novel dual tyrosine kinase inhibitor of FAK and IGF-IR, would suppress the growth and invasion of glioma cells.	TAE226	102-108	insulin like growth factor 1 receptor	Homo sapiens	161-167	
17431114-6	2007	TAE226 also inhibited IGF-I-induced phosphorylation of IGF-IR and activity of its downstream target genes such as MAPK and Akt.	TAE226	0-6	insulin like growth factor 1 receptor	Homo sapiens	55-61	
17431114-12	2007	Collectively, these data show that blocking the signaling pathways of FAK and IGF-IR with TAE226 has the potential to be an efficacious treatment for human gliomas.	TAE226	90-96	insulin like growth factor 1 receptor	Homo sapiens	78-84